AR044041A1 - Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina - Google Patents
Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosinaInfo
- Publication number
- AR044041A1 AR044041A1 ARP040101344A ARP040101344A AR044041A1 AR 044041 A1 AR044041 A1 AR 044041A1 AR P040101344 A ARP040101344 A AR P040101344A AR P040101344 A ARP040101344 A AR P040101344A AR 044041 A1 AR044041 A1 AR 044041A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- alkoxyalkyl
- hydroxyalkyl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente describe el uso de los compuestos de fórmula (1) en el tratamiento de enfermedades del SNC, en particular la enfermedad de Parkinson, solos o en combinación con otros agentes para el tratamiento de la enfermedad de Parkinson, y composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto que tiene la fórmula estructural (1) o su sal farmacéuticamente aceptable, en donde R es como se muestra en los restos de fórmulas (2); R1, R2, R3, R4 y R5 se seleccionan independientemente entre el grupo que consiste en H, alquilo y alcoxialquilo; R6 es H, alquilo, hidroxialquilo o -CH2F; R7, R8 y R9 se seleccionan independientemente entre el grupo que consiste en H, alquilo alcoxi, alquiltio, alcoxialquilo, halo y -CF3; Z es R10-arilo, R10-heteroarilo o como se muestra resto de fórmula (3); R10 es 1 a 5 sustituyentes seleccionados independientemente entre el grupo que consiste en H, alquilo, alquenilo, hidroxi, alcoxi, hidroxialquilo, hidroxialcoxi, alcoxialquilo, alcoxialcoxi, alcoxi-alcoxi-alquil-, (di-alcoxi)-alquilo, (hidroxi)-alcoxialquilo, R15-cicloalquilo, R15-cicloalquilalquilo, cicloalquil-oxi, cicloalquil-O-alcoxi, alquil-SO2-, alquil-SO-, halo, -CN, cianoalquilo, -CHF2, -CF3, -OCHF2, -OCF3, -C(O)R13, -O-alquilen-C(O)OR13, -C(O)O-alquilo, -N(R11)(R12), N(R11)(R12)-alquilo, -N(R11)(R12)-alcoxi, -C(O)N(R13)(R16), R11-heteroarilo, R15-heterocicloalquilo, R15-heterocicloalquil-alquilo, R15-heterocicloalquil-alcoxi, R15-heterocicloalquil-oxi, CF3-alquilen-O-alquilo, CF3-hidroxialquilo, (CF3)(hidroxi)alcoxi, ciano-alcoxi, -alquilen-C(O)-O-alquilo, -SO2-N(alquilo)2, (cicloalquil)hidroxialquilo, (hidroxialquil)alcoxi, (dihidroxi)alquilo, (dihidroxi)alcoxi, -C(=NOR17)-alquilo y -C(=NOR17)-CF3; o dos grupos R10 en átomos del anillo de C adyacentes juntos forman -O-CH2O-, -O-(CH2)2-O-, -CH2-O-(CH2)2-O-, -O-(CH2)2-, -(CH2)3-O-, -O-(CH2)3-O-, -(CH2)3-, en donde el anillo formado por los dos sustituyentes R10 y los átomos de C en el anillo al cual están unidos es sustituido con R16; o dos grupos R10 en átomos en el anillo de C adyacentes forman en forma conjunta -N(R11)-C(O)-O-, -N(R11)-C(O)-S-, -(CH2)2CH(OR18)-,-CH2CH(OR18)CH2-, -(CH2)3CH(OR18)-, -(CH2)2CH(OR18)CH2-, -(CH2)2C(O)-,-CH2C(O)CH2-, -(CH2)3C(O)-, -(CH2)2C(O)CH2-, -O(CH2)2CH(OR18)- o -OCH2CH(OR18)CH2-, en donde el anillo formado por dos sustituyentes R10 y los átomos de C en el anillo al cual están unidos es opcionalmente sustituido en un átomo de C por hidroxialquilo o alcoxialquilo; cada R11 se selecciona independientemente entre el grupo que consiste en H y alquilo; cada R12 se selecciona independientemente entre el grupo que consiste en H, alquilo, hidroxialquilo, alcoxialquilo, -C(O)-alquilo, -C(O)O-alquilo, (alcoxi)hidroxialquilo, alcoxialquil-C(O)-, -SO2alquilo, -alquilen-C(O)alquilo y -alquilen-C(O)O-alquilo; R13 es H, alquilo o -CF3; R14 es H, alquilo, alcoxialquilo, alquil-C(O)- o alcoxi-C(O)-; R15 es de 1 a 3 sustituyentes seleccionados independientemente entre el grupo que consiste en H, alquilo, -OH, alcoxi, alcoxialquilo e hidroxialquilo; o dos sustituyentes R15, tomados en forma conjunta con el C al cual ambos están unidos, forman un grupo -C(=O)-; R16 es H, alquilo, alcoxialquilo, OH o hidroxialquilo; R17 es H o alquilo; y R18 es H o alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46484003P | 2003-04-23 | 2003-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044041A1 true AR044041A1 (es) | 2005-08-24 |
Family
ID=33310963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101344A AR044041A1 (es) | 2003-04-23 | 2004-04-21 | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6897217B2 (es) |
| EP (1) | EP1622912B1 (es) |
| JP (2) | JP4527712B2 (es) |
| KR (1) | KR100831107B1 (es) |
| CN (1) | CN100503609C (es) |
| AR (1) | AR044041A1 (es) |
| AT (1) | ATE432282T1 (es) |
| AU (1) | AU2004233334B2 (es) |
| BR (1) | BRPI0409787B8 (es) |
| CA (1) | CA2522813C (es) |
| CL (1) | CL2004000847A1 (es) |
| CO (1) | CO5700766A2 (es) |
| CY (1) | CY1109263T1 (es) |
| DE (1) | DE602004021250D1 (es) |
| DK (1) | DK1622912T3 (es) |
| EC (1) | ECSP056115A (es) |
| ES (1) | ES2326270T3 (es) |
| HK (1) | HK1085466A1 (es) |
| HR (1) | HRP20090394T1 (es) |
| IL (1) | IL171567A (es) |
| MX (1) | MXPA05011366A (es) |
| MY (1) | MY139344A (es) |
| NO (1) | NO332182B1 (es) |
| NZ (1) | NZ542823A (es) |
| PE (1) | PE20050141A1 (es) |
| PL (2) | PL378867A1 (es) |
| PT (1) | PT1622912E (es) |
| RU (1) | RU2373210C2 (es) |
| SI (1) | SI1622912T1 (es) |
| TW (2) | TWI355381B (es) |
| WO (1) | WO2004094431A2 (es) |
| ZA (1) | ZA200508489B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7313588B1 (en) * | 2000-07-13 | 2007-12-25 | Biap Systems, Inc. | Locally executing software agent for retrieving remote content and method for creation and use of the agent |
| ES2336435T3 (es) * | 2001-11-30 | 2010-04-13 | Schering Corporation | Antagonista del receptor de adenosina a2a. |
| ATE490775T1 (de) * | 2002-12-19 | 2010-12-15 | Schering Corp | Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms |
| US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| TWI355381B (en) * | 2003-04-23 | 2012-01-01 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri |
| TW200538118A (en) * | 2004-04-21 | 2005-12-01 | Schering Corp | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| ATE556712T1 (de) | 2005-06-07 | 2012-05-15 | Kyowa Hakko Kirin Co Ltd | A2a antagonisten zur behandlung von motorischen störungen |
| AR057817A1 (es) * | 2005-09-19 | 2007-12-19 | Schering Corp | Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas |
| AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| US7723343B2 (en) | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
| WO2009111449A1 (en) * | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
| US8501997B2 (en) * | 2008-08-25 | 2013-08-06 | Air Products And Chemicals, Inc. | Curing agent for low temperature cure applications |
| US8512594B2 (en) * | 2008-08-25 | 2013-08-20 | Air Products And Chemicals, Inc. | Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s) |
| WO2010104194A1 (en) | 2009-03-10 | 2010-09-16 | Takeda Pharmaceutical Company Limited | Benzofuran derivatives |
| EP2462144B1 (en) | 2009-08-07 | 2017-09-20 | Merck Sharp & Dohme Corp. | PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN104136413B (zh) * | 2011-12-27 | 2016-10-26 | 比皮艾思药物研发有限公司 | 用于预防或治疗癫痫症的苯基氨基甲酸酯化合物 |
| WO2014101120A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| SI3269716T1 (sl) * | 2013-03-14 | 2020-12-31 | Galapagos N.V. | Nove spojine in farmacevtski sestavki le-teh za zdravljenje vnetnih motenj |
| EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
| WO2021011670A1 (en) * | 2019-07-17 | 2021-01-21 | Teon Therapeutics, Inc. | Adenosine a2a receptor antagonists and uses thereof |
| CN115160120A (zh) * | 2022-08-02 | 2022-10-11 | 乐威医药（江苏）股份有限公司 | 一种多烷氧基芳香酮的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US785906A (en) * | 1904-12-06 | 1905-03-28 | Albert P Mcbride | Casing packer and shoe for gas or oil wells. |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| DE69428977T2 (de) * | 1993-07-27 | 2002-07-11 | Kyowa Hakko Kogyo Kk | Arzneimittel gegen Parkinsonsche Krankheit |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| DE19826843A1 (de) * | 1998-06-16 | 1999-12-23 | Boehringer Ingelheim Pharma | Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| SI1283839T1 (es) * | 2000-05-26 | 2005-08-31 | Schering Corp | |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| KR20030076633A (ko) * | 2001-02-05 | 2003-09-26 | 가부시키 가이샤 오오쯔카 세이야쿠 고우죠우 | 트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법 |
| MXPA04003474A (es) | 2001-10-15 | 2004-07-30 | Schering Corp | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a. |
| ATE490775T1 (de) * | 2002-12-19 | 2010-12-15 | Schering Corp | Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms |
| TWI355381B (en) * | 2003-04-23 | 2012-01-01 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri |
-
2004
- 2004-04-21 TW TW093111142A patent/TWI355381B/zh not_active IP Right Cessation
- 2004-04-21 EP EP04760128A patent/EP1622912B1/en not_active Expired - Lifetime
- 2004-04-21 CL CL200400847A patent/CL2004000847A1/es unknown
- 2004-04-21 AT AT04760128T patent/ATE432282T1/de active
- 2004-04-21 PT PT04760128T patent/PT1622912E/pt unknown
- 2004-04-21 KR KR1020057019891A patent/KR100831107B1/ko active IP Right Grant
- 2004-04-21 BR BRPI0409787-4 patent/BRPI0409787B8/pt not_active IP Right Cessation
- 2004-04-21 MY MYPI20041463A patent/MY139344A/en unknown
- 2004-04-21 CN CNB2004800107535A patent/CN100503609C/zh not_active Expired - Fee Related
- 2004-04-21 SI SI200431189T patent/SI1622912T1/sl unknown
- 2004-04-21 US US10/829,416 patent/US6897217B2/en not_active Expired - Lifetime
- 2004-04-21 TW TW100131963A patent/TWI375677B/zh not_active IP Right Cessation
- 2004-04-21 DE DE602004021250T patent/DE602004021250D1/de not_active Expired - Lifetime
- 2004-04-21 PE PE2004000392A patent/PE20050141A1/es not_active Application Discontinuation
- 2004-04-21 NZ NZ542823A patent/NZ542823A/en not_active IP Right Cessation
- 2004-04-21 JP JP2006501291A patent/JP4527712B2/ja not_active Expired - Fee Related
- 2004-04-21 CA CA002522813A patent/CA2522813C/en not_active Expired - Fee Related
- 2004-04-21 WO PCT/US2004/012471 patent/WO2004094431A2/en active Application Filing
- 2004-04-21 RU RU2005136166/04A patent/RU2373210C2/ru not_active IP Right Cessation
- 2004-04-21 MX MXPA05011366A patent/MXPA05011366A/es active IP Right Grant
- 2004-04-21 DK DK04760128T patent/DK1622912T3/da active
- 2004-04-21 PL PL378867A patent/PL378867A1/pl unknown
- 2004-04-21 ES ES04760128T patent/ES2326270T3/es not_active Expired - Lifetime
- 2004-04-21 PL PL04760128T patent/PL1622912T3/pl unknown
- 2004-04-21 AR ARP040101344A patent/AR044041A1/es not_active Application Discontinuation
- 2004-04-21 AU AU2004233334A patent/AU2004233334B2/en not_active Ceased
-
2005
- 2005-05-23 US US11/135,261 patent/US7368449B2/en not_active Expired - Lifetime
- 2005-10-19 ZA ZA200508489A patent/ZA200508489B/en unknown
- 2005-10-21 CO CO05107374A patent/CO5700766A2/es active IP Right Grant
- 2005-10-21 EC EC2005006115A patent/ECSP056115A/es unknown
- 2005-10-26 IL IL171567A patent/IL171567A/en active IP Right Grant
- 2005-11-22 NO NO20055510A patent/NO332182B1/no not_active IP Right Cessation
-
2006
- 2006-03-21 HK HK06103531.4A patent/HK1085466A1/xx not_active IP Right Cessation
-
2009
- 2009-07-10 HR HR20090394T patent/HRP20090394T1/xx unknown
- 2009-08-04 CY CY20091100821T patent/CY1109263T1/el unknown
- 2009-11-04 JP JP2009253549A patent/JP2010059178A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044041A1 (es) | Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina | |
| AR048617A1 (es) | Antagonistas del receptor a2a de la adenosina con estructura de pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina. | |
| AU2017323584B2 (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| ES2302830T3 (es) | Derivados de 4-amino-6-fenil-pirrolo(2,3-d)pirimidina. | |
| AU2014400628B2 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| ES2656712T3 (es) | Novedoso compuesto sustituido con quinolina | |
| RU2646223C2 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| Semmelhack et al. | Total synthesis of Cephalotaxus alkaloids | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| RS53768B1 (en) | TRICYCLIC PI3K INHIBITORS AND USE PROCEDURES | |
| HRP20140437T1 (hr) | Bicikliäśki spojevi i njihove uporabe kao dualnih c-src/jak inhibitora | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| AR070526A1 (es) | Derivados de urea de benzomorfanos y estructuras relacionadas, una composicion farmaceutica que incluye al compuesto y un procedimiento de preparacion del mismo | |
| AR079636A1 (es) | Antagonistas del receptor ccr2 y usos de los mismos | |
| EA022753B1 (ru) | Имидазотиадиазолы для применения в качестве ингибиторов киназ | |
| AR084412A1 (es) | Compuestos de piridina fusionados, utiles como inhibidores de caseina quinasa, y las composiciones farmaceuticas que los contienen | |
| AR057817A1 (es) | Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas | |
| ES2845205T3 (es) | Métodos para preparar moduladores de receptores tipo Toll | |
| ES2247304T3 (es) | Compuestos heterociclicos y mejoradores de la funcion cerebral que los contienen como ingrediente activo. | |
| AR046753A1 (es) | Derivados de benzoxazina y usos de los mismos | |
| JP4721452B2 (ja) | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 | |
| AR048526A1 (es) | Antagonistas de nk1 de anillo de piperidina o pirrolidina fusionado, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades relacionadas con los receptores de neuroquinina nk1 | |
| AR073741A1 (es) | Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis | |
| WO2005087775A1 (ja) | 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物 | |
| AR038117A1 (es) | Agentes antivirales derivados de la 4- oxo-4,7 -dihidrofuro [2,3-b]piridin-5-carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |